MDR A. baumannii

Acinetobacter baumannii has emerged as a predominant cause of hospital-acquired infections worldwide, posing a significant challenge due to its extraordinary ability to acquire resistance to multiple antibiotics. According to recent data, infections caused by multidrug-resistant A. baumannii lead to increased morbidity, longer hospital stays, and higher healthcare costs. Carbapenems and tigecycline have historically provided reliable treatment for A. baumannii infections; however, recent global trends indicate a significant increase in carbapenem and tigecycline resistance among circulating isolates

鲍曼不动杆菌（Acinetobacter baumannii）已成为全球范围内医院获得性感染的主要病原菌，因其具备获得多重抗生素耐药性的极强能力，给临床诊疗带来了严峻挑战。据近期研究数据显示，多重耐药鲍曼不动杆菌引发的感染会导致患者发病率升高、住院时长延长，且医疗成本显著增加。碳青霉烯类（Carbapenems）与替加环素（tigecycline）曾是治疗鲍曼不动杆菌感染的可靠药物；然而近期全球流行趋势表明，当前流行的临床分离菌株对碳青霉烯类及替加环素的耐药性正显著上升。